Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients.
OBJECTIVE
To determine the serum levels of adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome versus healthy controls and to see the relation of them with each other and with the metabolic syndrome components.


METHODS
Adiponectin and plasminogen activator inhibitor-1 levels were measured in 53 subjects with metabolic syndrome and 30 healthy controls by ELISA. All subjects of metabolic syndrome had the criterias of metabolic syndrome (obesity, insulin resistance, hypertension, dyslipidemia, glucose metabolism disorders). Adiponectin and plasminogen activator inhibitor-1 levels in serum were compared between the groups and relations of them with each other, with metabolic syndrome components, also HbA1c and C peptide were examined. For statistical analysis student-t test and pearson's correlations were used.


RESULTS
Metabolic syndrome group had significantly lower adiponectin and higher plasminogen activator inhibitor-1 levels than healthy controls (p<0.001). There was no difference between the average age of both groups. There was an inverse relationship between plasma adiponectin and plasminogen activator inhibitor-1 ( r= -0.653, p<0.001). Also adiponectin levels were inversely correlated with body mass index (BMI), waist and hip circumferences, systolic and diastolic pressures, fasting plasma glucose, 2 hour postprandial serum glucose, HbA1c, C peptide, triglycerides, total cholesterol, insulin and insulin resistance (HOMA). Plasminogen activator inhibitor-1 levels were correlated positively with these parameters.


CONCLUSIONS
Hypoadiponectinemia and elevated plasminogen activator inhibitor-1 levels were closely associated with the metabolic syndrome and its components, inverse relationship was present between adiponectin and plasminogen activator inhibitor-1 levels in metabolic syndrome patients. It is suggested that measuring and regulating the plasma concentration of adiponectin and plasminogen activator inhibitor-1 may be useful for management of the metabolic syndrome so this may prevent the development of obesity, cardiovascular diseases and diabetes.
Bilgili
Sibel
S
The Ministry of Health, Izmir Education and Research Hospital, Clinical Biochemistry Department, Turkiye. bilgili.sibel@yahoo.com.tr
Celebiler
Aydan C
AC
Dogan
Aylin
A
Karaca
Baysal
B
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D002096:C-Peptide / Q000097:blood; D016022:Case-Control Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D024821:Metabolic Syndrome / Q000097:blood*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011446:Prospective Studies
D052242:Adiponectin; D002096:C-Peptide; D006442:Glycated Hemoglobin; D017395:Plasminogen Activator Inhibitor 1; C517652:hemoglobin A1c protein, human